On the 6th, TaiMed Biologics announced a strategic partnership with Helios Pharmaceutical for the introduction of its innovative HIV treatment, Trogarzo, in Vietnam. Due to confidentiality agreements between the two parties, specific terms of the collaboration were not disclosed. Under the agreement, Helios Pharmaceutical will be responsible for obtaining marketing authorization for Trogarzo in the designated region, as well as overseeing its promotion and commercialization.

TaiMed Biologics noted that Helios Pharmaceutical is one of Vietnam’s leading pharmaceutical distributors. The company is dedicated to improving patient access to innovative medicines and aligning Vietnam’s healthcare system with international standards. Helios strategically focuses on delivering advanced pharmaceutical solutions to ensure high-quality healthcare reaches patients throughout the country. To fulfill this mission, Helios has established a robust and reliable distribution network capable of efficiently supplying a wide range of medicines to the Vietnamese market. The company works closely with government agencies, hospitals, and healthcare professionals to develop innovative treatments that address unmet medical needs.

King-Ming Chang, CEO of TaiMed Biologics, stated that Trogarzo holds an important market position in the treatment of multi-drug resistant (MDR) HIV. The collaboration with Helios Pharmaceutical ensures that this groundbreaking therapy can reach the patients who need it most.

Chang emphasized that TaiMed Biologics is committed to changing lives and bringing hope to patients worldwide through Trogarzo. The partnership with Helios marks a new chapter in expanding life-saving treatments and highlights the company’s anticipation for Trogarzo’s impact on Vietnam’s healthcare landscape.

Resource: 中裕新藥與Helios公司策略合作 越南合推抗愛滋病新藥